Adjunctive Mindfulness-Based Intervention Reduces Anxiety and Improves Sleep, Cognition in Medicated GAD Patients — Randomized Trial

When Tianjin Anding Hospital's research team assigned 106 medicated adults with generalized anxiety disorder to either a group mindfulness program or structured psychoeducation, the question was not whether mindfulness works in the abstract. It was whether it adds anything clinically meaningful for patients already on stable pharmacotherapy. The answer, from a completed randomized controlled trial, was a measurable yes.

Participants in the mindfulness arm finished the 8-week program with a mean Hamilton Anxiety Rating Scale (HAMA) score of 18.6, compared with 22.5 in the active psychoeducation control group, a statistically significant difference (P < 0.05). The linear mixed model confirmed a group-by-time interaction estimate of -3.68, a result that clinicians familiar with HAMA benchmarks will recognize as meaningful beyond the threshold of statistical convention.

The intervention was adapted from mindfulness-based cognitive therapy (MBCT) and delivered in group format across the eight weeks, with training focused specifically on attention regulation and acceptance skills. Those two capacities, the researchers argue, are the likely drivers of downstream improvement in emotion regulation and sleep disruption, both central features of chronic GAD. All 53 participants in the mindfulness arm continued their existing medication throughout, making the design a true adjunctive test rather than a comparison against pharmacotherapy alone.

Every secondary outcome also favored the mindfulness group. Self-reported anxiety on the Zung Self-Rating Anxiety Scale improved significantly, as did Five Facet Mindfulness Questionnaire scores confirming actual skill acquisition, not just reported wellbeing. Sleep quality on the Pittsburgh Sleep Quality Index, negative cognitive bias on the NCPBQ, and psychosocial functioning on the GAF-M all showed statistically significant between-group differences. That range of gains, spanning clinician-rated severity, self-report, sleep architecture, thought patterns, and functional capacity, places this study in a different category from trials that track symptom scores alone.

The active control design is what sharpens the finding. Rather than comparing mindfulness against a passive waitlist, the Tianjin team matched it against structured psychoeducation, a credible, therapist-delivered alternative. Gains in the mindfulness arm therefore reflect training in mindfulness skills specifically, not group participation or clinical attention in general.

For clinicians, the study offers a practical framework for introducing adjunctive mindfulness to medicated GAD patients who remain symptomatic. The multi-domain outcome profile provides concrete, patient-facing language: this format produced statistically robust improvements in clinician-rated anxiety, sleep quality, cognitive bias, and day-to-day functioning within eight weeks of group-based practice. The finding that benefits extended to psychosocial functioning, measured by the GAF-M, is particularly relevant for patients whose medication has plateaued at symptom management without fully restoring daily life. Framing adjunctive MBI as a structured skill-building program, rather than a replacement for or critique of medication, tends to lower resistance and align with how most mindfulness research now positions the intervention: not instead of pharmacotherapy, but alongside it.